ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
Company to host corporate update webcast to share results on December 11, 2024
公司將於2024年12月11日舉行企業更新網絡研討會，分享成果
LAUSANNE, Switzerland, Dec. 6, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), today announced that it will host a conference call and live webcast on Wednesday, December 11, 2024, at 8:30 a.m. EST to provide an update on preliminary data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
瑞士洛桑，2024年12月6日 / PRNewswire / - adc therapeutics SA（紐交所：adct）今日宣佈，將於2024年12月11日上午8:30舉辦電話會議和現場網絡直播，以更新LOTIS-7階段10億開放標籤臨床試驗的初步數據，該試驗評估了在複發性或難治性瀰漫大b細胞淋巴瘤（r / r DLBCL）患者中，ZYNLONTA與雙特異性抗體glofitamab（COLUMVI）聯合使用的安全性和有效性。
To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.
要參加電話會議，請在此註冊。北美和加拿大的參與者免費撥打電話號碼爲1-800-836-8184。建議您在活動開始前10分鐘加入，儘管您可以隨時進行預先註冊。電話會議的實時網絡直播將在 adc therapeutics 網站的投資者部分「事件和演示文稿」下提供，網址爲ir.adctherapeutics.com。電話會議後，網絡直播將保留30天。
About ADC Therapeutics
關於ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics（紐交所：ADCT）是一家商業化階段的全球領先者和先鋒，致力於抗體藥物結合物（ADCs）領域。公司正在推進其專有ADC技術，改變對患有血液惡性腫瘤和實體瘤患者的治療範式。
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics的CD19-定向ADC ZYNLONTA (loncastuximab tesirine-lpyl) 已獲得FDA的加速批准和歐洲委員會的有條件批准，用於治療兩條或以上全身療法經治療失敗或複發性瀰漫大B細胞淋巴瘤。ZYNLONTA還在與其他藥物聯用及早期治療方案的開發中。除了ZYNLONTA外，ADC Therapeutics還有多個ADC正在進行臨床和臨床前開發。
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit and follow the Company on LinkedIn.
adc therapeutics 總部位於瑞士洛桑（Biopôle），在倫敦和新澤西設有運營。欲了解更多信息，請訪問 並在社交媒體上關注公司。LinkedIn.
ZYNLONTA is a registered trademark of ADC Therapeutics SA.
ZYNLONTA是adc therapeutics SA的註冊商標。
CONTACTS:
聯繫方式：
Investors
Marcy Graham
ADC Therapeutics
[email protected]
+1 650-667-6450
投資者
馬西·格雷厄姆
ADC Therapeutics
[email protected]
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
[email protected]
+1 862-926-9040
媒體
Nicole Riley
ADC Therapeutics
[email protected]
+1 862-926-9040
SOURCE ADC Therapeutics SA
adc therapeutics SA來源
